The components which make up Indigo Biosciences assay kits

View the slide viewer

Human PGR Reporter Assay Kit

SIZES SKU
1 x 96-well format assays IB05001
3 x 32 assays in 96-well format IB05001-32
1 x 384-well format assays IB05002
View All Product Documentation
Get Pricing

Product Description and Product Data

This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Progesterone Receptor (PGR). INDIGO’s PGR reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the PGR. In addition to PGR Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human PGR. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.

Features

  • Clear, Reproducible Results

  • All-Inclusive Assay Systems
  • Exceptional Cell Viability Post-Thaw
  • Consistent Results Lot to Lot

Product Specifications

Target TypeNuclear Hormone Receptor
SpeciesHuman
Receptor FormNative
Assay ModeAgonist, Antagonist
Kit Components
  • PGR Reporter Cells
  • Cell Recovery Medium (CRM)
  • Compound Screening Medium (CSM)
  • Progesterone, (ref. agonist; in DMSO)
  • Detection Substrate
  • Detection Buffer
  • White, sterile, cell-culture ready assay plate
Shelf Life6 months
Orthologs AvailableYes
Shipping RequirementsDry Ice
Storage temperature-80C

Data

Agonist dose-response analyses of Human PGR. Agonist dose-response of Human PGR Reporter Cells using Progesterone (provided), and Nomegestrol acetate (Tocris). Concentrated stocks prepared in DMSO were serially diluted in 5-fold decrements using CSM. Final assay concentrations for progesterone-treated cells ranged between 1,000 nM and 64 pM; assay concentrations of nomegestrol ranged between 40 nM and 2.6 pM. Luminescence was quantified and average relative light units (RLU) and their corresponding values of standard deviation (SD), Fold-Activation and Percent Relative Activation were determined for each treatment group (n = 3). Z’ values were calculated as described by Zhang, et al. (1999). GraphPad Prism software was used to curve-fit data using the least-squares method of non-linear regression, and EC50 values were determined. High Z' scores confirm the robust performance of this PGR Assay.
Validation of PGR Assay antagonist dose-response. Antagonist analysis of PGR Reporter Cells using the reference compounds Mifepristone (Cayman Chem.) and PF-02413873 (Sigma-Aldrich). Reporter cells were exposed to a fixed ~ EC80 concentration of the challenge agonist Progesterone and varying concentrations of the reference antagonists. All treatments were performed in triplicate. The Live Cell Multiplex (LCM) assay confirmed that no compound-induced cytotoxicity occurred (data not shown).

Target Background

INDIGO’s Human Progesterone Receptor (PGR) Reporter Assay System utilizes proprietary mammalian cells engineered to provide constitutive, high-level expression of human PGR (NR3C3), a ligand-dependent transcription factor.

INDIGO’s Reporter Cells include the luciferase reporter gene functionally linked to a PGR-responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in PGR activity. Luciferase gene expression occurs after ligand-bound PGR undergoes nuclear translocation, DNA binding, recruitment and assembly of the co-activators and accessory factors required to form a functional transcription complex, culminating in expression of the target gene. Unlike in vitro binding assays, and some other cell-based assay strategies, the readout from INDIGO’s reporter cells demands the same orchestration of all intracellular molecular interactions and events that can be expected to occur in vivo.

Citations

Tris(1,3-dichloro-2-propyl) phosphate is a metabolism-disrupting chemical in male mice

Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) is an organophosphate flame retardant. The primary TDCPP metabolite, bis(1,3-dichloro-2-propyl) phosphate (BDCPP), is detectable in the urine of over 90 % of Americans. Epidemiological studies show sex-specific associations between urinary BDCPP levels and metabolic syndrome, which is an established risk factor for type 2 diabetes, heart disease, and stroke. We used a mouse model to determine whether TDCPP exposure disrupts glucose homeostasis. Six-week old male and female C57BL/6J mice were given ad libitum access to diets containing vehicle (0.1 % DMSO) and TDCPP resulting in the following treatment groups: 0 mg/kg/day, 0.02 mg/kg/day, 1 mg/kg/day, or 100 mg/kg/day. After being on the experimental diet for five weeks without interruption, body composition was analyzed, glucose and insulin tolerance tests were performed, and fasting glucose and insulin levels were quantified. TDCPP at 100 mg/kg/day caused male sex-specific adiposity, fasting hyperglycemia, and insulin resistance. TDCPP-induced modulation of nuclear receptor activation was investigated using an in vitro screen to identify potential mechanisms of metabolic disruption. TDCPP activated farnesoid X receptor (FXR) and pregnane X receptor (PXR), and inhibited the androgen receptor (AR). PXR target genes, but not FXR target genes, were upregulated in livers from mice exposed to 100 mg TDCPP/kg/day. Interestingly, PXR target genes were differentially expressed in livers from both males and females. It remains to be determined whether TDCPP-induced metabolic disruption occurs via modulation of nuclear receptor activity. Taken together, these studies build upon the association of TDCPP exposure and metabolic syndrome in humans by identifying sex-specific effects of TDCPP on glucose homeostasis in mice.
2022-12-07

Bioactive Rearrangement Products from Aqueous Photolysis of Pharmaceutical Steroids

In an ongoing effort to study the environmental fate of endocrine-active steroid hormones, we report the formation of phenolic rearrangement products (3 and 4) with a novel 6,5,8,5-ring system following aqueous photolysis of dienogest (1) and methyldienolone (2). The structures were established by analysis of 2D NMR and HRMS data, and that of 3 was confirmed by X-ray diffraction analysis. These photoproducts exhibit progestogenic and androgenic activity, albeit with less potency than their parent compounds.
2019-04-25

Also available as a service

Progesterone Receptor (PGR, NR3C3)

Learn More About Services